Theravance Biopharma Inc

Stock Chart, Company Information, and Scan Results

$14.40(as of Sep 15, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Theravance Biopharma Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$14.40
Ticker SymbolTBPH
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees97
CountyUSA
Market Cap$720.2M

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes of medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.

Theravance Biopharma Inc In Our Stock Scanner

As of Sep 16, 2025
As of ---
As of ---
As of ---
As of ---
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
As of ---
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.